[Role of ketotifen in the immunotherapy of atopic asthmatics].
The place of KETOTIFEN in the immunotherapy for atopic asthmatic patients (confirmed by cutaneous test and RAST) has been determined by a study conducted on 48 patients divided into two randomly selected parallel groups. Group one received 2 mg/d. Ketotifen treatment together with a desensitization. Group two: only had a specific hyposensitization treatment. The study was contacted over a period of 18 weeks and showed that the number of local reaction in group one was half as numerous as in group two. In conclusion, KETOTIFEN may be practised an immunotherapy to house dust and acarians, without any difficulties, and with a fast progression.
Haddad
G
G
Service de pneumologie, Centre Hospitalier, La Rochelle.
Pacaud
D
D
Papeix
P
P
Tran
Q
Q
Vincent
J
J
Steeg
L F
LF
D000293:Adolescent; D000328:Adult; D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D003888:Desensitization, Immunologic / Q000379:methods; D004391:Dust / Q000009:adverse effects; D005260:Female; D006801:Humans; D007665:Ketotifen / Q000627:therapeutic use*; D008297:Male; D008925:Mites / Q000276:immunology; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000628:therapy; D012882:Skin Tests
D004391:Dust; D007665:Ketotifen
Place du kétotifène dans l'immunothérapie chez des asthmatiques atopiques.